These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22426455)

  • 1. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
    Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
    Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
    Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
    Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expeditious Generation of Biparatopic Common Light Chain Antibodies
    Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
    Front Immunol; 2020; 11():606878. PubMed ID: 33424853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.
    Godar M; Morello V; Sadi A; Hultberg A; De Jonge N; Basilico C; Hanssens V; Saunders M; Lambrecht BN; El Khattabi M; de Haard H; Michieli P; Blanchetot C
    Sci Rep; 2016 Aug; 6():31621. PubMed ID: 27546726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models.
    DaSilva JO; Yang K; Perez Bay AE; Andreev J; Ngoi P; Pyles E; Franklin MC; Dudgeon D; Rafique A; Dore A; Delfino FJ; Potocky TB; Babb R; Chen G; MacDonald D; Olson WC; Thurston G; Daly C
    Clin Cancer Res; 2020 Mar; 26(6):1408-1419. PubMed ID: 31848185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
    Kearns JD; Bukhalid R; Sevecka M; Tan G; Gerami-Moayed N; Werner SL; Kohli N; Burenkova O; Sloss CM; King AM; Fitzgerald JB; Nielsen UB; Wolf BB
    Mol Cancer Ther; 2015 Jul; 14(7):1625-36. PubMed ID: 25911688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
    Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
    Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.
    Shi SY; Lu YW; Liu Z; Stevens J; Murawsky CM; Wilson V; Hu Z; Richards WG; Michaels ML; Zhang J; Yan W; Li Y
    J Biol Chem; 2018 Apr; 293(16):5909-5919. PubMed ID: 29483191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system.
    Asano R; Nakayama M; Kawaguchi H; Kubota T; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    FEBS J; 2012 Jan; 279(2):223-33. PubMed ID: 22074399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
    Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
    Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
    Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms.
    Stefano JE; Lord DM; Zhou Y; Jaworski J; Hopke J; Travaline T; Zhang N; Wong K; Lennon A; He T; Bric-Furlong E; Cherrie C; Magnay T; Remy E; Brondyk W; Qiu H; Radošević K
    J Biol Chem; 2020 Dec; 295(52):18379-18389. PubMed ID: 33122192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
    LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
    MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.